5-Ethynyl-2'-deoxyuridine (EdU) Clinical Trials

Size	Price	Qty
100mg	USD 257
1g	USD 670

Clinical Trials

Multiple clinical trials are currently evaluating diverse therapeutic interventions for metabolic syndrome, anxiety disorders, and refractory chronic cough, with recruitment statuses ranging from not yet recruiting to actively recruiting. The trial landscape includes a Phase 3 clinical trial for refractory chronic cough sponsored by Bellus Health Inc., a GSK company. Additionally, several clinical trials of non-phased design are examining intensive lifestyle interventions sponsored by Taiwanese medical institutions for metabolic syndrome, alongside gamified cognitive training for adolescent anxiety supported by Swiss and international academic organizations.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06271200	Not yet recruiting	Metabolic Syndrome	National Health Research Institutes Taiwan\|Tri-Service General Hospital\|Chang Gung Memorial Hospital\|National Taiwan University Hospital Hsin-Chu Branch\|Taichung Armed Forces General Hospital	2024-02-20	Not Applicable
NCT05923944	Not yet recruiting	Anxiety\|Anxiety Disorders and Symptoms	School of Health Sciences Geneva\|University of Geneva Switzerland\|University of Haifa\|Swiss National Science Foundation	2024-01	Not Applicable
NCT05599191	Recruiting	Refractory Chronic Cough	Bellus Health Inc. - a GSK company	2022-10-25	Phase 3

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 5-Ethynyl-2'-deoxyuridine (EdU) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a nucleoside thymidine analog, 5-ethynyl-2'-deoxyuridine incorporates into newly synthesized genomic DNA during S-phase replication, providing a reactive alkyne moiety for copper-catalyzed click chemistry detection. This selective incorporation allows precise quantification of cellular proliferation and DNA synthesis dynamics, supporting the evaluation of proliferative cellular responses in research relevant to metabolic syndrome, anxiety disorders, and refractory chronic cough.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).